寡转移性前列腺癌放射治疗建议:ESTRO-ACROP 德尔菲共识
欧洲放射肿瘤学会(ESTRO)指南委员会组织前列腺癌放疗专家通过德尔菲问卷就41个争议问题达成共识,推荐PSMA PET作为首选分期与再分期影像,并在新发寡转移、寡复发和寡进展情形下对淋巴结、骨和内脏转移推荐转移灶定向治疗,同时讨论了放疗剂量、体积和技术。
要点
- 专家组共识推荐前列腺特异性膜抗原正电子发射断层扫描(PSMA PET)作为首选的 staging 与再分期影像。
- 对新发寡转移、寡复发和寡进展的淋巴结、骨及内脏转移,推荐转移灶定向治疗(MDT)策略。
- 共识对放疗剂量、体积和技术进行了讨论与评述,旨在标准化寡转移性前列腺癌的放疗。
核心结论
- 这些建议旨在提供标准化与共识,以优化寡转移性前列腺癌的放射治疗,直至随机试验的成熟结果可用。
研究设计与样本
- 欧洲放射肿瘤学会(ESTRO)指南委员会由前列腺癌放疗专家组成,被要求回答一份包含41个问题的专用问卷,涵盖寡转移性前列腺癌的主要争议问题。
主要发现
- 专家组就患者选择以及常规使用前列腺特异性膜抗原正电子发射断层扫描(PSMA PET)作为首选分期和再分期影像达成共识。
- 推荐在新发寡转移、寡复发和寡进展疾病情形下,对淋巴结、骨和内脏转移采用转移灶定向治疗(MDT)策略。
- 对放射治疗的剂量、体积和技术进行了讨论和评述。
关键数值与推荐
- 问卷包含41个问题,涉及寡转移性前列腺癌的主要争议问题。
- 共识推荐PSMA PET作为首选的 staging 和再分期影像。
- 推荐在新发寡转移、寡复发和寡进展情形下,对淋巴结、骨和内脏转移采用MDT策略。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出目前仅发表了少数前瞻性随机研究。
- 原文指出缺乏强力的I级证据。
- 原文指出MDT在临床实践中的广泛使用主要基于回顾性和小型2期研究。
- 原文指出不同中心之间存在很大差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Oligometastatic prostate cancer is a new and emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective and small phase 2 studies and with a large difference across centers. Pending results of ongoing prospective randomized trials, there is a clear need for more consistent treatment indications and radiotherapy practices. MATERIAL AND METHODS: A European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee consisting of radiation oncologists' experts in prostate cancer was asked to answer a dedicated questionnaire, including 41 questions on the main controversial issues with regard to oligometastatic prostate cancer. RESULTS: The panel achieved consensus on patient selection and routine use of prostate-specific membrane antigen positron emission tomography (PSMA PET) imaging as preferred staging and restaging imaging. MDT strategies are recommended in the de novo oligometastatic, oligorecurrent and oligoprogressive disease setting for nodal, bone and visceral metastases. Radiation therapy doses, volumes and techniques were discussed and commented. CONCLUSION: These recommendations have the purpose of providing standardization and consensus to optimize the radiotherapy treatment of oligometastatic prostate cancer until mature results of randomized trials are available.
引用
- Zilli T, Achard V, Dal Pra A, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022. PMID: 36228761. doi:10.1016/j.radonc.2022.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。